Biotech company AngioSoma announced today the appointment of a new CEO who brings extensive healthcare experience with hospitals, health insurance organizations and physicians' offices.
Ken Stephenson, who began duties about a month ago, also serves as president of the company and a board member, according to a statement from the company, based in Montgomery, Texas.
In addition to Stephenson’s appointment, Alexanderia Blankenship was named COO and executive vice president.
“Working with Ken for the last month and a half, providing him due diligence, and working on AngioSoma’s operational plan has been a pleasure,” Blankenship said in a statement. “I believe that Ken will be able to accelerate the company’s ability to secure funding, and bring our ‘end to end’ solution to market.”
Stephenson has worked with interventional radiologists and cardiologists, giving him expertise to bridge that gap between AngiSoma and medical professionals, the company said.
Senior Writer
As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.